Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate whether these results translate to clinical practice, data were pooled from ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferenci, Peter, Bourgeois, Stefan, Buggisch, Peter, Norris, Suzanne, Curescu, Manuela, Larrey, Dominique, Marra, Fiona, Kleine, Henning, Dorr, Patrick, Charafeddine, Mariem, Crown, Eric, Bondin, Mark, Back, David, Flisiak, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849558/
https://www.ncbi.nlm.nih.gov/pubmed/30739368
http://dx.doi.org/10.1111/jvh.13080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849558/
https://www.ncbi.nlm.nih.gov/pubmed/30739368
http://dx.doi.org/10.1111/jvh.13080

Ejemplares similares